# Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis

> **NCT00411424** · PHASE1,PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 54 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ASK8007
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00411424
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411424, "Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00411424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*